Platelets in psychiatric disorders

Daniela Ehrlich, Christian Humpel

Daniela Ehrlich, Christian Humpel, Department of Psychiatry and Psychotherapy, Laboratory of Psychiatry and Exp. Alzheimers Research, Anichstr. 35, A-6020 Innsbruck, Austria

Author contributions: Both Ehrlich D and Humpel C contributed to this paper.

Correspondence to: Christian Humpel, Professor, Department of Psychiatry and Psychotherapy, Laboratory of Psychiatry and Exp. Alzheimers Research, Anichstr. 35, A-6020 Innsbruck, Austria. christian.humpel@i-med.ac.at

Telephone: +43-512-50423712 Fax: +43-512-50423713
Received: November 20, 2011 Revised: June 14, 2012
Accepted: July 21, 2012
Published online: December 22, 2012

Abstract
Several parallels exist between platelets and the brain, which make them interesting for studying the neurobiology of psychiatric disorders, such as Alzheimer’s disease, depression, schizophrenia and anxiety disorders. Platelets store, secrete and process the amyloid precursor protein which is cleaved into the β-amyloid (Aβ) peptides. The accumulation of Aβ in brain (plaques) and vessels (Aβ-angiopathy) is a major hallmark in AD. Platelets contain high amounts of serotonin and a dysfunction of the serotoninergic system is involved in the development of several behavior disorders, such as depression, anxiety disorders and self aggressive disturbances. Furthermore, platelets are able to take up dopamine and express various dopamine receptors, which make them to an interesting tool to study the underlying mechanisms of schizophrenia. In summary, platelets are an interesting and easily accessible cell type to study changes related to different psychiatric disorders and platelets proteins may be useful as diagnostic biomarkers for some psychiatric disorders.

© 2012 Baishideng. All rights reserved.

Key words: Platelets; Psychiatric disorders; Amyloid precursor protein; Serotonin; Inflammation

Peer reviewer: Gianluca Serafini, MD, Department of Neurosciences, Mental Health and Sensory Organs-Sant’Andrea Hospital, “Sapienza” University of Rome, Via di Grottarossa1035-1039, 00189 Rome, Italy

Ehrlich D, Humpel C. Platelets in psychiatric disorders. World J Psychiatr 2012; 2(6): 91-94 Available from: URL: http://www.wjgnet.com/2220-3206/full/v2/i6/91.htm DOI: http://dx.doi.org/10.5498/wjp.v2.i6.91

Platelets Characterization

Platelets are small unucleated blood cells with a size of approximately 3 µm originating from megacaryocytes in the bone marrow, from where they are released into the blood system. Platelets are easily to isolate from the whole blood by different centrifugation step. They possess several important organelles, in which large amounts of proteins are stored and released after platelets activation with different agonists, such as collagen or thrombin. The dense bodies contain serotonin, adenosine-diphosphat, adenosine-triphosphat and calcium, whereas the α-granules comprise the highest amount of proteins including von Willebrandt factor, fibronectin, fibrinogen, P-selectin, platelet derived growth factor (PDGF), amyloid-precursor protein, matrix-metalloproteinases, various coagulation and growth factors as well as inflammatory markers. Platelets organelles content is mostly taken up from the plasma, however, platelets are also able to synthesize molecules, such as PDGF, platelet activating factor-4, β-thromboglobulin and thrombospondin. In addition, platelets express various receptors on their surface, including α-2 and β-2 adrenoreceptors, serotonin-, benzodiazepine- and fibrinogen receptors.

In order to characterize isolated platelets the well established platelet markers CD61, CD41 and CD62P were commonly used. CD61 is expressed on resting platelets and serves as a subunit of the receptor for fibrinogen and is also known as the integrin β3 unit which forms together with CD41 the gpⅢα/Ⅱb complex[10]. These glycoproteins are found on platelets and megacaryocytes mediating cell adhesion and binding of fibrinogen to this receptor.
CD62P is stored in α-granules of platelets and is a calcium-dependent protein that migrates during platelet activation to the plasma membrane where it mediates platelets interaction with endothelial cells or leukocytes. Binding of biochemical agonists or shear stress induces changes in the plasma membrane (shape change) and results in platelet activation and secretion of granule contents (Figure 1). Platelets are able to adhere to the sub-endothelial matrix after vessel wall injury, which induces activation and formation of the hemostatic plug by aggregation (Figure 1). In first line platelets function includes hemostasis [2], but they also participate in inflammatory processes by releasing cytokines [3]. The transport, metabolism, and release of several bioaminergic neurotransmitters (e.g., serotonin) are similar in platelets and neurons and thus platelets serve as a diagnostic tool and an interesting research model in several psychiatric disorders.

**PLATELETS IN ALZHEIMER’S DISEASE**

Alzheimer’s disease (AD) is a neurodegenerative disorder, which is the most common cause of dementia in the elderly [4,5]. Neuropathology includes β-amyloid (Aβ) plaques in brain and vessels, neurofibrillary tangles with hyperphosphorylated tau protein [6], inflammation [7] and cerebrovascular damage [8]. Platelets are an interesting tool to study the cellular mechanisms of AD, because they contain highest levels of the precursor of β-amyloid (APP) compared to all peripheral tissues [9-12] and all three isoforms of APP (130, 110 and 106 kDa) are detectable in platelets [9,13]. Full length APP is cleaved by a Ca2+ dependent cysteine protease during platelet activation [10] and APP processing is altered in patients suffering from AD [14] resulted in a reduced ratio between the 130 kDa and 106-110 kDa APP isoform [11], suggesting that APP ratios in platelets could be a biomarker for AD. See Review on platelets biomarker in AD [15] and Review on APP as a potential biomarker in AD [16].

**PLATELETS IN DEPRESSION**

The relationship between depression and platelets function has been in focus, because platelets share many...
Platelets in Schizophrenia

The pathophysiology of schizophrenia is not well understood and there is an increasing body of evidence that several molecular pathways are involved. However, the most common hypothesis proposes a link between the disease and excessive levels of dopamine. Platelets may serve as an interesting research tool to investigate underlying mechanisms of schizophrenia, because they possess several dopamine receptors and are able to store and release dopamine. Interestingly, platelets of schizophrenic patients show morphological alterations accompanied by the formation of big vacuoles and increased glycogen levels most likely pointing to an altered glycogen metabolism. Oxidative stress may also play a role in development of schizophrenia and accumulation of reactive oxygen species may influence platelets function and reactivity. Indeed, the response of platelets to ADP and collagen is different in schizophrenic patients compared to healthy controls. See review Asor and Ben-Shachar (this issue) on platelets in schizophrenia.

Platelets in Anxiety and Suicide

The hypothesis of an involvement of the noradrenergic and serotoninergic system in the pathophysiology of anxiety disorders suggests platelets an important role in the study of anxiety disorders. A decreased serotoninergic function with vulnerability towards the development of aggression most likely resulting in the self-aggressive behavior of suicide attempters may be involved in the pathogenesis of suicidality. An inverse relationship between the serotonin metabolite 5-hydroxyindoleacetic acid (5HIAA) levels in the cerebrospinal fluid and the past history of suicide attempts may once more link serotoninergic dysfunction and suicide.

Taken together, platelets are an interesting and easily accessible tool to model neuronal function in the periphery and to study neurobiol of several psychiatric disorders which are mostly related to changes in the brain neurotransmitter systems.

REFERENCES

1. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb/IIIa complex during platelet activation. J Biol Chem 1985; 260: 11107-11114
2. Ware JA, Coller BS. Platelet morphology, biochemistry and function. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, editors. Williams hematology. New York: McGraw-Hill, 1995: 1161-1199
3. Horstman LL, Wy J, Ahn YS, Zivadinov R, Maghzi AH, Ettemadifar M, Steven Alexander J, Minagar A. Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation 2010; 7: 10
4. Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology 1998; 51: 728-733
5. Dubois MF, Hébert R. The incidence of vascular dementia in Canada: a comparison with Europe and East Asia. Neuroepidemiology 2001; 20: 179-187
6. Burns A, Byrne EJ, Maurer K. Alzheimer’s disease. Lancet 2002; 360: 163-165
7. McGee EG, McGee PL. Inflammatory processes in Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 741-749
8. Jellinger KA. Alzheimer disease and cerebrovascular path:ology—an update. J Neural Transm 2002; 109: 813-836
9. Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Millward E, Currie J, Armes D, Weidemann A, Fischer P. The amyloid precursor protein of Alzheimer’s disease is released by human platelets. J Biol Chem 1990; 265: 15977-15983
10. Li QX, Evin G, Small DH, Multhaup G, Beyreuther K, Masters CL. Proteolytic processing of Alzheimer’s disease beta A4 amyloid precursor protein in human platelets. J Biol Chem 1995; 270: 14110-14117
11. Borroni B, Agosti C, Marcelli E, Di Luca M, Padovani A. Blood cell markers in Alzheimer Disease: Amyloid Precursor Protein form ratio in platelets. Exp Gerontol 2010; 45: 53-56
12. Vignini A, Sartini D, Morganti S, Nanetti L, Luzzi S, ProvinciaIi L, Mazzanti L, Emanuelli M. Platelet amyloid precursor protein isoform expression in Alzheimer’s disease: evidence for peripheral marker. Int J Immunopathol Pharmacol 2011; 24: 529-534
13. Hochstrasser T, Ehrlich D, Marksteiner J, Sperner-Unterweger B, Humpel C. Matrix Metalloproteinase-2 and Epidermal Growth Factor are Decreased in Platelets of Alzheimer Patients. Curr Alzheimer Res 2011; Epub ahead of print
14. Tangu K, Hyman LS, Baskin F, Rosenberg RN. Platelet amyloid precursor protein processing: a bio-marker for Alzheimer’s disease. J Neurol Sci 2006; 240: 53-58
15. Talib LL, Joaquim HPG, Forlenza OV. Platelet biomarkers in Alzheimer’s disease. World J Psychiatry 2012; 2: 95-101
16. Evin G, Li QX. Platelets and Alzheimer’s disease: Potential of APP as a biomarker. World J Psychiatry 2012; 2: 102-113
17. Ziegelmstein RC, Parakh K, Sakhua A, Bhat U. Platelet function in patients with major depression. Intern Med J 2009; 39: 38-43
18. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37: 12-16
19. Strike PC, Steptoe A. Psychosocial factors in the development of coronary artery disease. Prog Cardiovasc Dis 2004; 46: 337-347
20. Ziegelmstein RC, Parakh K, Sakhua A, Bhat U. Depression and coronary artery disease: is there a platelet link? Mayo Clin Proc 2007; 82: 1366-1368
Ehrlich D et al. Platelets in psychiatric disorders

21 Parakh K, Sakhuja A, Bhat U, Ziegelstein RC. Platelet function in patients with depression. *South Med J* 2008; **101**:612-617

22 Williams MS. Platelets and depression in cardiovascular disease: A brief review of the current literature. *World J Psychiatry* 2012; **2**:114-123

23 Mesa CS. Schizophrenia: cytopathological diagnosis valuation scale. *Carib Med J* 1998; **60**:29-32

24 Dietrich-Muszalska A, Olas B. The changes of aggregability of blood platelets in schizophrenia. *World J Biol Psychiatry* 2009; **10**:171-176

25 Asor E, Ben-Shachar D. Platelets: A possible glance into brain biological processes in schizophrenia. *World J Psychiatry* 2012; **2**:124-133

26 Lauterbach E, Brunner J, Hawellek B, Lewitzka U, Ising M, Bondy B, Rao ML, Frahnert C, Rujescu D, Müller-Oerlinghausen B, Schley J, Heuser I, Maier W, Hohagen F, Felber W, Bronisch T. Platelet 5-HT2A receptor binding and tryptophan availability in depression are not associated with recent history of suicide attempts but with personality traits characteristic for suicidal behavior. *J Affect Disord* 2006; **91**:57-62

27 Anguelova M, Benkelfat C, Turecki G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. *Mol Psychiatry* 2003; **8**:646-653

28 Pandey GN. Altered serotonin function in suicide. Evidence from platelet and neuroendocrine studies. *Ann N Y Acad Sci* 1997; **836**:182-200

29 Marazziti D, Dell’Osso B, Baroni S, Masala I, Di Nasso E, Giannaccini G, Conti L. Decreased density of peripheral benzodiazepine receptors in psychiatric patients after a suicide attempt. *Life Sci* 2005; **77**:3268-3275

30 Koudouovoh-Tripp P, Sperner-Unterweger B. Influence of mental stress on platelet bioactivity. *World J Psychiatr* 2012; **2**:134-147

S-Editor Lu YJ L-Editor A E-Editor Zheng XM